Pharmaceutical Uses of Palmitoyl Carnitine
By analyzing the metabolomics of maternal tissues during primate pregnancy and combining it with palmitoylcarnitine to promote progenitor cell growth and differentiation, the problem of predicting and treating adverse outcomes during pregnancy has been solved, and effective treatment and regeneration of tissue damage during pregnancy has been achieved.
Patent Information
- Application Number
- CN202211373664.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-11-03
AI Technical Summary
Current technologies lack methods to predict and effectively intervene in adverse pregnancy outcomes at an early stage, especially due to insufficient understanding of maternal physiological adaptations during pregnancy, leading to high morbidity or mortality rates in both mothers and fetuses. Furthermore, rodent studies cannot fully reflect the pregnancy status of primates/humans.
By performing non-targeted metabolomics analysis on multiple maternal tissues during primate pregnancy, we can reveal metabolic pathways and metabolites, verify their biomedical relevance to various human progenitor cells, and utilize palmitoylcarnitine to promote progenitor cell growth and differentiation, thereby preparing drugs for the prevention and treatment of diseases related to tissue damage during pregnancy.
Successfully treats gestational heart disease, gestational diabetes, and gestational liver disease; promotes tissue regeneration during pregnancy; and reduces the morbidity and mortality of adverse pregnancy outcomes.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present application relates to the field of pharmacological research, and specifically to the use of palmitoylcarnitine in the preparation of drugs for preventing and treating diseases associated with tissue damage during mammalian pregnancy. Background Art
[0002] During pregnancy, the mother undergoes a variety of physiological changes and metabolic adaptations, and any small deviation from normal values may lead to an increased risk of adverse pregnancy outcomes (Chang and Streitman, 2012; von Versen-Hoeynck and Powers, 2007; Zeng et al., 2017). For example, placental-related hypertensive disorders complicate 6-8% of pregnancies, of which approximately 2% develop into preeclampsia (Verbeek and Verbeek, 2014), while cardiovascular disease complicates 1-4% of pregnancies (Ramlakhan et al., 2020), both of which may lead to significant increases in maternal and fetal morbidity or mortality. Despite substantial improvements in global healthcare and sanitation standards over the years, global analyses estimate that 1,800 newborns and 216 mothers per 100,000 live births still die from various pregnancy complications (Alkema et al., 2016; Hug et al., 2019). Current clinical approaches to diagnosing adverse pregnancy complications are primarily based on ultrasound imaging (Bricker and Neilson, 2000), clinical hematology testing (Liu et al., 2012), and clinical blood biochemistry testing (Larsson et al., 2008), but few methods are able to provide sufficiently early predictions for preventive intervention, and even fewer intervention therapies are currently available. This is in part due to divergences in our basic understanding of the physiological adaptations that occur in the mother during normal pregnancy.
[0003] Previous transcriptomic studies have shown that during pregnancy in mice, metabolism-related genes in maternal organs and the placenta undergo significant changes (Paquette et al., 2018; Patel et al., 2011). In addition, it is known that multiple maternal organs undergo complex metabolic interactions and dynamic changes during pregnancy (Aasa et al., 2015; Ellery et al., 2015; Papacleovoulou et al., 2017; Saoi et al., 2020). Although rodent studies have deepened our basic understanding of pregnancy, they do not fully reflect the real situation in primates / humans because the organ physiology of primates is very different from that of rodents, especially the rapidly evolving placenta during pregnancy (Hemberger et al., 2020; Sieck, 2019). In contrast, cynomolgus macaques are considered to be a highly reliable primate model for studying human physiology because they are well conserved in evolution, genome, structure, physiology, and metabolism (Wagner et al., 2006; Yan et al., 2011). In addition, their reproductive characteristics are more similar to humans, such as follicular development, ovulation cycle, monochorionic placental structure and physiology, and even macaque chorionic gonadotropin (mCG) can be detected in the placenta of cynomolgus monkeys, which is similar to human chorionic gonadotropin (hCG) (Buse and Markert, 2019; Mihm et al., 2011; Wilken et al., 2002). Similar to humans, cynomolgus monkeys also have menstruation and can conceive throughout the year, and the pregnancy cycle of single births is relatively long (Weinbauer et al., 2008; Yoshida et al., 2010), which is very different from multiparous rodents. Therefore, cynomolgus monkeys are considered to be the most relevant animal model for studying the physiology and pathology of primate / human pregnancy (Grossmann et al., 2020).
[0004] Several metabolomics studies on normal human maternal blood samples revealed some metabolic changes and candidate bioactive molecules in the blood ( et al., 2021; Liang et al., 2020; Lindsay et al., 2015; Orczyk-Pawilowicz et al., 2016; Wang et al., 2016). However, due to the inability to directly access maternal organs and tissues during pregnancy, no systematic analysis of metabolomic changes in multiple gestational stages and multiple maternal tissues in primates has been conducted to date, and the metabolomic adaptation of primate maternal tissues during normal pregnancy remains poorly understood. In this study, we revealed the non-targeted metabolomic characteristics of 23 maternal tissues at different stages of primate pregnancy, systematically described and analyzed the changes in metabolic coupling between multiple maternal tissues during primate pregnancy, and identified new metabolic pathways and metabolites associated with maternal tissues at various stages of primate pregnancy. In addition, we further verified the biomedical relevance of some differential metabolites to various human progenitor cells. Our study provides new insights into the metabolic homeostasis of primates during pregnancy, comprehensively reveals the metabolic network evolution, pathway adaptation, and regulation of some key primate metabolites in pregnant maternal tissues, and lays the foundation for a better understanding of how primate mothers adapt to the metabolic challenges brought about by pregnancy. Summary of the invention
[0005] Based on the above objectives, this application provides:
[0006] 1. The application of palmitoyl carnitine in the preparation of drugs for preventing and treating diseases related to tissue damage during mammalian pregnancy.
[0007] 2. The use according to item 1, wherein the disease associated with tissue damage during mammalian pregnancy is selected from the group consisting of gestational heart disease, gestational diabetes, and gestational liver disease.
[0008] 3. The use according to any one of items 1 to 2, wherein the mammal is a human.
[0009] 4. The use according to any one of items 1-2, wherein the mammal is from human-raised animals; preferably selected from the following group: pigs, cows, horses, dogs, cats, goats, rabbits, cynomolgus macaques, mice, and rats; most preferably cynomolgus macaques.
[0010] 5. The use according to item 1, wherein the palmitoyl carnitine achieves tissue regeneration by promoting the growth and differentiation of progenitor cells when tissue is damaged during pregnancy.
[0011] 6. Use of a compound that promotes the increase of palmitoylcarnitine levels in mammals in the preparation of a drug for preventing and treating diseases associated with tissue damage during mammalian pregnancy.
[0012] 7. The use according to item 6, wherein the disease associated with tissue damage during mammalian pregnancy is selected from the group consisting of gestational heart disease, gestational diabetes, and gestational liver disease.
[0013] 8. The use according to any one of items 6 to 7, wherein the mammal is a human.
[0014] 9. The use according to any one of items 6-7, wherein the mammal is from human-raised animals; preferably selected from the following group: pigs, cows, horses, dogs, cats, goats, rabbits, cynomolgus macaques, mice, and rats; most preferably cynomolgus macaques.
[0015] 10. The use according to any one of items 6-7, wherein the compound that promotes the increase of palmitoylcarnitine levels in mammals is a palmitoylcarnitine synthesis promoter and / or a palmitoylcarnitine decomposition inhibitor; wherein,
[0016] Preferably, the palmitoylcarnitine synthesis promoter is a carnitine palmitoyltransferase I (CPT-1) activator, and most preferably baicalin or its derivatives;
[0017] Preferably, the palmitoylcarnitine decomposition inhibitor is a carnitine palmitoyltransferase II (CPT-2) inhibitor, most preferably 4-trimethylammoniumbutyrate.
[0018] Beneficial technical effects achieved by the technical solution of this application
[0019] In the present application, palmitoyl carnitine is used in pharmaceutical preparations to unexpectedly promote the growth and differentiation of tissue progenitor cells during pregnancy, and successfully treat heart disease during pregnancy, diabetes during pregnancy, and liver disease during pregnancy. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 shows the clustering analysis of non-targeted metabolomics data of single samples in four periods, namely non-pregnancy (NP), early pregnancy (EP), mid-pregnancy (MP), and late pregnancy (LP), according to the tissue origin and systematic classification of the samples; A and B t-distribution-stochastic neighbor embedding (t-SNE) and partial least squares discriminant analysis (PLS-DA) cluster the metabolomes of single samples according to the tissue origin of the samples; C. PLSDA clusters the metabolomes of single samples according to systematic classification; D. Spearman correlation coefficient is used as a distance metric to calculate the average intensity of each metabolite in three biological replicates of 23 maternal tissues in four periods, and hierarchical clustering is performed on the metabolomes of each tissue in each period; EH. PLS-DA clusters the metabolomes of single samples according to the gestational period; IL. LC / MS total ion chromatograms of the same quality control (QC) sample and placenta sample.
[0021] Figure 2 shows the correlation analysis of the metabolome data of 23 maternal tissues in four periods; AD. The correlation heat map shows the metabolic coupling of 23 maternal tissues in four periods, including NP, EP, MP and LP; EH. The correlation network diagram shows the metabolic coupling of 23 maternal tissues in four periods, including NP, EP, MP and LP; IL. The collected maternal tissues of cynomolgus monkeys and the number of missing values of metabolites in each tissue.
[0022] Figure 3 is the metabolic pathway analysis of 23 maternal tissues during pregnancy identified by MSEA in MetaboAnalystR; A. heat map shows the number of metabolic pathways that are significantly changed in the 23 maternal tissues (NP, MP and LP vs EP, P<0.05); B. bubble chart shows 8 metabolic pathways that are significantly changed in NP, MP and LP vs EP groups in more than half of the maternal tissues tested; C. heat map shows the other metabolic pathways that are significantly changed in more than half of the maternal tissues tested in NP, MP and LP vs EP groups, except for the 8 pathways in B; D. heat map shows other metabolic pathways that are significantly changed in more than half of the maternal tissues tested in LP vs EP, except for B and C.
[0023] Figure 4 Figure 2 shows the number of differential metabolites (difference ≥ 1.5) of 23 maternal tissues at MP and LP compared with EP; from the outside to the inside, the first ring shows the type of tissue, and different colors represent the organs of tissue origin. The second ring shows the total metabolic characteristics determined for the 23 tissues at the four stages. The numbers in the third ring show the total number of metabolites determined in each tissue. The numbers in the fourth ring show the number of differential metabolites shared by each tissue at MP and LP compared with EP. The white numbers in the innermost ring show the number of differential metabolites shared by the 23 tissues at MP and LP compared with EP.
[0024] Figure 5 Fold changes in palmitoylcarnitine metabolic abundance in 23 tissues during pregnancy and its effects on the functions of different human progenitor cells; A. Fold changes in palmitoylcarnitine metabolic abundance in NP, MP and LP of 23 maternal tissues compared with EP; B. RT-qPCR analysis of mRNA expression levels of Tbx3, Afp, Hnf4a, Hnf1b, FAH and ALB in liver progenitor cells (LPCs) treated with dimethyl sulfoxide, 25 and 50 μM palmitoylcarnitine (PC); C. RT-qPCR analysis of mRNA expression levels of Tbx3, Afp, Hnf4a, Hnf1b, FAH and ALB in liver progenitor cells (LPCs) treated with dimethyl sulfoxide, 25 and 50 μM palmitoylcarnitine (PC); mRNA expression levels of Pax3, Pax7, MyoD1, MyoG, NCAM1, and ACTA1 in skeletal muscle cells (MCs) treated with dimethyl sulfoxide, 25 and 50 μM palmitoylcarnitine (PC); D. RT-qPCR analysis of the mRNA expression levels of NKX2-5, ISL1, and Tnnt2 in cardiomyocytes (CMs) treated with dimethyl sulfoxide, 25 and 50 μM palmitoylcarnitine (PC); E. RT-qPCR analysis of the mRNA expression levels of PDX1, RFX6, and PAX4 in pancreatic progenitor cells (PPCs) treated with dimethyl sulfoxide, 25 and 50 μM palmitoylcarnitine (PC). DETAILED DESCRIPTION
[0025] The specific embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although the specific embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to enable the scope of the present invention to be fully communicated to those skilled in the art.
[0026] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the difference in the functions of the components as the criterion for distinction. As mentioned throughout the specification and claims, "including" or "comprising" is an open term, so it should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present invention, but the description is based on the general principles of the specification and is not intended to limit the scope of the present invention. The scope of protection of the present invention shall be determined by the attached claims.
[0027] As used herein, "substantially free" with respect to a particular component is used herein to mean that the particular component is not purposefully formulated into the composition and / or is present only as a contaminant or in trace amounts. Thus, the total amount of the particular component resulting from any accidental contamination of the composition is less than 0.05%, preferably less than 0.01%. Most preferred are compositions in which the amount of the particular component is undetectable by standard analytical methods.
[0028] As used in this specification, "a" or "an" may mean one or more. As used in the claims, when used with the word "comprising", the word "a" or "an" may mean one or more than one.
[0029] The term "or" is used in the claims to mean "and / or" unless explicitly stated to refer only to alternatives or the alternatives are mutually exclusive, although the present disclosure supports a definition referring only to alternatives and "and / or." As used herein, "another" may mean at least a second or more.
[0030] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method used to determine the value, or the variation that exists between study subjects.
[0031] The methods for obtaining various biological materials described in the examples are only provided as an experimental method to achieve the specific disclosed purpose, and should not be construed as limiting the sources of the biological materials of the present invention. In fact, the sources of the biological materials used are extensive, and any biological material that can be obtained without violating laws and moral ethics can be replaced and used according to the instructions in the examples.
[0032] In a first aspect, the present application relates to the use of palmitoylcarnitine in the preparation of medicines.
[0033] In one specific embodiment, there is provided a use of palmitoylcarnitine in the preparation of a medicament for preventing and treating diseases associated with tissue damage during mammalian pregnancy.
[0034] In the context of this specification, "palmitoylcarnitine" has the following characteristics:
[0035] The structural formula is:
[0036]
[0037] CAS number: 2364-67-2
[0038] English name: PALMITOYL CARNITINE
[0039] The molecular formula is: C23H46NO4
[0040] In another specific embodiment, the disease associated with tissue damage during pregnancy in the mammal is selected from the group consisting of gestational heart disease, gestational diabetes, and gestational liver disease.
[0041] In the context of this specification, heart disease during pregnancy, diabetes during pregnancy and liver disease during pregnancy conform to the general definitions in this technical field.
[0042] During pregnancy or after childbirth, the incidence of heart disease will increase accordingly, and peripartum cardiomyopathy is the main cause of death in pregnant women, accounting for 23% of deaths in late pregnancy. With the delay of gestational age, the proportion of pregnancy complicated with coronary artery disease, especially acute coronary syndrome, increases year by year, and the incidence and mortality rate increase year by year; therefore, pregnancy can be regarded as a risk factor for heart disease; heart disease during pregnancy will be observed to produce myocardial tissue damage. In the embodiments of the present application, the applicant observed from the dose-dependent increase in the expression of ISL1 and TNNT2 that palmitoyl carnitine induces the specialization and differentiation of myocardial cells, which indicates that it can promote the growth and regeneration of the maternal heart during pregnancy and thus repair the tissue damage of the myocardium.
[0043] Gestational diabetes is a special type of diabetes that poses a high risk to pregnant women and fetuses. Affected by the special physiological mechanism of pregnancy, the blood sugar level of this type of diabetes patients fluctuates greatly and is difficult to control. If they cannot receive effective treatment in time, it will lead to serious adverse pregnancy outcomes. Moreover, comparing the prognosis of healthy pregnant women and pregnant women with gestational diabetes, the latter has a significantly increased risk of complications such as diabetes and cardiovascular disease. According to research, pre-pregnancy BMI ≥ 25kg / m 2 , family history of diabetes, high serum Leptin level, and low serum APN level are all risk factors for gestational diabetes; when diabetes occurs during pregnancy, pancreatic tissue damage will be observed. The examples of this application prove that palmitoyl carnitine can induce the specialization and terminal differentiation of pancreatic β islet cells, and the increase in PAX4 and RFX6 expression indicates that it can promote the regeneration of maternal pancreatic β islets during normal pregnancy.
[0044] Adaptive physiological changes during pregnancy can lead to increased liver fragility, weakened buffering capacity, and accelerated disease progression. Liver disease during pregnancy has always been an independent factor leading to maternal mortality; during pregnancy, 3% to 9% of pregnant women are affected by some form of liver disease, some of which are fatal to mother and child; they can be roughly divided into three types: one is liver disease directly related to pregnancy, which can occur at a specific time during pregnancy; the second is liver disease unrelated to pregnancy, which can occur at any time, such as viral or drug-induced hepatitis; the third is pregnancy occurring in women with a history of liver disease; due to the pathophysiological specificity of pregnancy itself, the liver's own strong compensatory ability and the concealment of the early stage of the disease, pregnancy-related liver disease is easily overlooked by obstetricians in the early stage, and once significant clinical symptoms appear, the liver has been severely damaged, or even liver failure; in summary, when liver disease occurs during pregnancy, tissue damage to the liver will be observed. In the examples of the present application, it can be seen that for hepatic progenitor cells, palmitoylcarnitine can significantly induce terminal differentiation of hepatic progenitor cells into hepatocytes expressing ALB, as observed from the dose-dependent increase in ALB expression, indicating that it can accelerate tissue regeneration after maternal liver injury.
[0045] In yet another specific embodiment, the mammal is a human.
[0046] In another specific embodiment, the mammal is from human-bred animals; preferably selected from the following group: pigs, cows, horses, dogs, cats, goats, rabbits, cynomolgus monkeys, mice, and rats; most preferably, cynomolgus monkeys.
[0047] In a specific embodiment, the palmitoyl carnitine achieves tissue regeneration by promoting the growth and differentiation of progenitor cells when tissue is damaged during pregnancy.
[0048] In the context of this specification, "progenitor cell" refers to a stem cell that exists in adult tissue and has a relatively clear differentiation target. Before the cell is completely differentiated, it can be transformed into a certain intermediate cell, which is called a progenitor cell or precursor cell. Progenitor cells belong to adult stem cells and are undifferentiated multipotent or multipotent stem cells. Unlike stem cells, the differentiation of progenitor cells has more clarity, that is, they can only differentiate into some target cells. Another important difference between them is that stem cells can proliferate indefinitely, while the number of progenitor cell divisions is limited. Progenitor cells exist in various adult tissues of organisms and are responsible for the repair and regeneration process after tissue damage. After the damage occurs, the progenitor cells can be mobilized and activated, proliferate in large quantities and migrate to the damaged part, differentiate into mature cells, and replace the damaged tissue. Corresponding progenitor cells have been identified in various tissues and organs of the human body, for example: blood progenitor cells, skin progenitor cells, small intestinal progenitor cells, lung progenitor cells, etc. The embodiments of the present application show the effect of palmitoyl carnitine on liver progenitor cells, myocardial progenitor cells and pancreatic progenitor cells.
[0049] In a second aspect, the present application relates to the use of compounds for promoting the increase of palmitoylcarnitine levels in mammals.
[0050] In one embodiment, provided is the use of a compound that promotes the increase of palmitoylcarnitine levels in a mammal in the preparation of a drug for preventing and treating diseases associated with tissue damage during mammalian pregnancy.
[0051] In yet another specific embodiment, the disease associated with tissue damage during mammalian pregnancy is selected from the group consisting of gestational heart disease, gestational diabetes, and gestational liver disease.
[0052] In yet another specific embodiment, said mammal is a human.
[0053] In a specific embodiment, the mammal is from an animal raised by humans; preferably selected from the group consisting of pigs, cows, horses, dogs, cats, goats, rabbits, cynomolgus monkeys, mice, and rats; most preferably, cynomolgus monkeys.
[0054] In another specific embodiment, the compound that promotes the increase of palmitoylcarnitine levels in mammals is a palmitoylcarnitine synthesis promoter and / or a palmitoylcarnitine decomposition inhibitor; wherein,
[0055] Preferably, the palmitoylcarnitine synthesis promoter is a carnitine palmitoyltransferase I (CPT-1) activator, and most preferably baicalin or its derivatives;
[0056] Preferably, the palmitoylcarnitine decomposition inhibitor is a carnitine palmitoyltransferase II (CPT-2) inhibitor, most preferably 4-trimethylammoniumbutyrate.
[0057] In the context of this specification, "baicalin" has the following characteristics:
[0058] The structural formula is:
[0059]
[0060] CAS number: 21967-41-9
[0061] English name: Baicailin
[0062] The molecular formula is: C21H18O11
[0063] In the context of this specification, "4-trimethylammonium butyrate" has the following structural features:
[0064]
[0065] in
[0066] A1 is O or a bond,
[0067] m is selected from 3, 4, 5, 6, 7, 8, 9 and 10,
[0068] n is selected from 1, 2, 3, 4 and 5,
[0069] R1 is an aryl group selected from phenyl and naphthyl, said aryl group being unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group consisting of lower alkyl, halogen, lower haloalkyl and phenyl, or
[0070] heteroaryl selected from the group consisting of pyridyl, thienyl and thiazolyl, said heteroaryl being unsubstituted or substituted by 1, 2 or 3 groups selected from lower alkyl, halogen, lower haloalkyl, lower oxyalkyl and phenyl,
[0071] The term "lower" refers to a group consisting of 1 to 7 carbon atoms.
[0072] and pharmaceutically acceptable salts thereof.
[0073] Examples
[0074] Experimental methods:
[0075] Animal Ethics Statement
[0076] All experiments were in accordance with the principles for the ethical treatment of nonhuman primates and were approved in advance by the Institutional Animal Care and Use Committee of the Institute of Zoology (Chinese Academy of Sciences) (IOZ-IACUC-2021-184).
[0077] Animal sample collection
[0078] Healthy female cynomolgus macaques were mated with healthy male cynomolgus macaques, and sexual intercourse was confirmed by the presence of spermatozoa in the naked eye or vaginal smear during copulation. The gestational period was determined by B-ultrasound, including early pregnancy (EP, 5-8 weeks, N = 3), mid-pregnancy (MP, 12-15 weeks, N = 3), and late pregnancy (LP, 18-20 weeks, N = 3). A total of 9 naturally pregnant and 3 non-pregnant female cynomolgus macaques (5-8 years old, weighing 2.5-6.0 kg) were housed in the Xieerxin Biological Resources Institute (Beijing, China), which has obtained certification for laboratory animal care. All animals were housed in a room maintained at 23 ± 3 °C and using a 12-h light / 12-h dark cycle. Under the continuous supervision of a veterinarian, they were fed fruits and vegetables once a day and given tap water twice a day. None of the monkeys had a history of clinical diseases or other experimental history that could affect physiological metabolism before the experiment. Before collecting samples, the monkeys were anesthetized with ketamine hydrochloride at a dose of 10-12 mg / kg. Ultrasound examination was performed by a professional veterinarian to confirm the pregnancy period again. Whole blood samples were obtained from the femoral vein and divided into non-heparinized tubes and allowed to clot for 30 minutes, and then centrifuged at 2000g for 10 minutes in a 4°C centrifuge to collect serum samples. After ensuring that the animals were completely under deep anesthesia, blood was drawn through the femoral artery to induce euthanasia. Serum and another 22 tissues were immediately snap-frozen in liquid nitrogen and stored in a -80°C freezer until metabolomics analysis.
[0079] Liquid chromatography-mass spectrometry (LC-MS) metabolomics
[0080] The metabolite extraction protocol was based on the protocol of Shyh-Chang et al. (Shyh-Chang et al., 2013). Briefly, the mass and volume of the sample were measured and then combined with the same volume of 80% (v / v) methanol-water at -78°C. The mixture was treated with 316 stainless steel beads (Gering, Beijing, China) precooled at -78° in a TissuePrep 24 homogenizer and then immersed in liquid nitrogen for 1-5 minutes at a vibration frequency of 100 Hz. After homogenization, the lysate was centrifuged at 5000g for 15 minutes, and the supernatant was collected for LC-MS analysis.
[0081] An Acquity I ultra-high performance liquid chromatography (UPLC) system coupled with a Xevo G2-XS high-resolution quadrupole time-of-flight hybrid mass spectrometer (Waters) was used for non-targeted metabolite analysis. Reverse phase chromatography was performed using a T3 column (Acquity UPLC HSST3, length 2.1 × 100 mm, particle size 1.7 μm) with the following solvents: mobile phases A (100% water) and B (100% acetonitrile) both contained 0.1% formic acid, with the following elution gradient: 0 min 95% A; 8.5 min 50% A; 12 min 2% A; 16 min 95% A. The flow rate was 0.4 ml / min, and the sample load was 2 μl.
[0082] The mass spectrometer was used for data acquisition using UPLC / MS E in positive and negative ESI modes, allowing the acquisition of parent and product ion data in a single injection. Typical source conditions for maximum intensity of precursor ions were as follows: capillary voltage, 2.5 kV positive mode and 2.0 kV negative mode; sample cone, 40 V; source temperature, 120 °C; desolvation temperature, 20 °C; cone gas flow, 30 L / h; desolvation gas (N2) flow rate, 800 L / h. All analyses were performed using lockspray to ensure accuracy and reproducibility. Leucine-enkephalin (5 ng / ml) was used as a lock mass to generate reference ions (positive ion mode: m / z 556.2771; negative ion mode: m / z 554.2615) and was introduced by lockspray at a rate of 10 μl / min to obtain accurate mass numbers. MS data were acquired using MS E The MS data were acquired in two separate scans with separate collision energies. Scan 1 (low energy): 50-1200 mass scan range; 0.2 sec scan time; 6 eV collision energy; Scan 2 (high energy): 50-1200 mass scan range; 0.2 sec scan time; collision energy slope of 10-40 eV. Acquiring MS data in this manner allows analysis of both parent ions and fragment ions. MS data processing was performed using Progenesis QI software (Nonlinear Dynamics, Waters). The raw data were imported into Progenesis QI for peak alignment and peak picking and high-resolution MS analysis based on the accurate charge mass number (m / z). E The data is matched.
[0083] Quality Assessment of Metabolomics Data
[0084] For further analysis, the raw metabolomics data were normalized by intensity summation and logarithmic transformation, and partial least squares discriminant analysis (PLS-DA) was performed using MetaboAnalystR (Pang et al., 2021) (https: / / github.com / xia-lab / MetaboAnalystR). In our analysis, missing metabolite values in any sample were replaced with zero. A total of 11,852 metabolic features were detected in 23 tissues. T-distributed stochastic neighbor embedding (t-SNE) (Melit Devassy et al., 2020) was used for unsupervised clustering of the raw data, and the above analysis used the Rtsne and ggplot2 packages ( Figure 1A ).
[0085] Spearman correlation analysis
[0086] We averaged the intensities of all identified metabolites for each sample and constructed a hierarchical clustering dendrogram using the Spearman correlation coefficient as the distance norm metric and complete linkage in MetaboAnalystR. To further determine metabolic correlations, we constructed correlation matrices for the 23 tissues across the four stages within each tissue and visualized them using correlation heatmaps and network plots in the R environment with a data-defined threshold of 0.185. Correlation heatmaps were drawn using the pheatmap package, and correlation network plots were generated using the qgraph package (Epskamp et al., 2012).
[0087] Pathway enrichment analysis
[0088] We used MetaboAnalystR to perform metabolite enrichment analysis (MSEA) (Xia and Wishart, 2010) on all identified metabolites in 23 tissues of NP, MP, and LP, with EP as the baseline for comparison. To quantify pathway activity, we counted the number of significantly changed metabolic pathways (P < 0.05) and visualized them using the pheatmap package. In addition, we used the ggplot2 package to create bubble plots and heat maps to visualize the important metabolic pathways that were significantly changed in more than half of the tissues we tested at at least one stage of pregnancy.
[0089] Identification of significantly altered metabolites
[0090] MetaboAnalystR was used to perform fold change (FC) analysis, which was calculated based on the ratio of the mean abundance of all metabolites in a specific tissue relative to the EP. To quantify the results, we counted the number of metabolites that were significantly changed (FC ≥ 1.5) in the MP and LP relative to the EP in each tissue, plotted them on circular stacked bar graphs using the tidyverse and viridis packages, and visualized Venn diagrams using the UpSetR package to show the number of intersecting metabolites (Conway et al., 2017).
[0091] Cell culture
[0092] Human liver, muscle, heart, and pancreatic progenitor cells were induced from pluripotent WA07 human ESCs (WiCell, USA), and all cells were cultured according to the detailed procedures described previously (Ang et al., 2018; Chua et al., 2019; Koh et al., 2016; Martin et al., 2020). After one day of passaging, 25 or 50 μM palmitoylcarnitine (PC) or dimethyl sulfoxide was added to the culture medium, and all cells were cultured for another 2 days before RNA extraction.
[0093] Quantitative real-time PCR analysis
[0094] Total RNA was extracted from cells according to the instructions of FastPure Cell / Tissue Total RNA Isolation Kit V2 (RC112), and 1 μg of total RNA was reverse transcribed into cDNA using HiScript III All-in-one RT SuperMix Perfect for qPCR kit (R333-01). Real-time quantitative polymerase chain reaction (qRT-PCR) was then performed using LightCycler 480System Real Time PCRSystem (Roche, LC-480, USA) and SYBR Premix Ex Taq II (TakaraBio). The expression level of mRNA was calculated using the ΔΔCT method, and GAPDH was used as an internal control. Each gene was repeated at least three times, and the results were presented in bar graphs. Statistical analysis was performed using the t-test, and the error bars represent the mean ± SEM.
[0095] Key Resources List
[0096]
[0097]
[0098] Key Commercial Kits
[0099]
[0100] software
[0101]
[0102] Example 1 Metabolomics analysis of maternal tissues at different stages of pregnancy in cynomolgus monkeys
[0103] To study the metabolic adaptation of maternal tissues during primate pregnancy, we chose to analyze maternal tissues from cynomolgus monkeys at different gestational stages and constructed adult cynomolgus monkey models corresponding to the three periods of human pregnancy (early, mid, and late), with three in each group. Twenty-three maternal tissues from 10 organ systems were collected from 9 pregnant and 3 non-pregnant cynomolgus monkeys, including uterus, ovary, placenta, mammary gland, thymus, apex of the heart, left ventricle, left atrium, right ventricle, right atrium, pancreatic head, pancreatic neck, pancreatic body, pancreatic tail, liver, kidney, adrenal gland, spinal cord, gastrocnemius, quadriceps, abdominal skin, head skin, and serum ( Fig.2I Compared with non-pregnant women, the total weight of the uteroplacental system and its organ coefficient increase throughout pregnancy (Mayhew, 2006), while the total weight of the thymus and its organ coefficient decrease in the second and third stages of pregnancy ( Figure 2J and 2K ), which may be related to key adaptive mechanisms regulating the maternal immune system (Dixit et al., 2003). However, the weights of the heart, liver, kidney, and pancreas did not change significantly ( Figure 2J and 2K A total of 273 samples were analyzed for non-targeted metabolomics by liquid chromatography-mass spectrometry (LC-MS). After peak alignment, filtering, quality control, and normalization preprocessing ( Figure 1A ), showing that a total of 11,852 metabolic features were identified in 23 tissues at four stages. Among them, 1,468 features were detected and annotated in all tissues ( Figure 2L ). Both t-distributed stochastic neighbor embedding (t-SNE) and partial least squares discriminant analysis (PLS-DA) showed that samples can be distinguished based on tissue origin ( Figure 1A and 1B ), which confirms the reliability of the quality of our metabolomics analysis solution ( Figure 1A and 1B ). PLS-DA also showed that tissue samples could also be well clustered together based on their organ system of origin ( Figure 1C ), further confirming the reliability of our LC-MS metabolomics data. Together, these results suggest metabolic correlations among maternal tissues. To elucidate the hierarchical relationships between each tissue, we created a dendrogram of each tissue across all stages ( Figure 1D). Interestingly, we found that the 23 maternal tissues could be divided into three clusters, which appeared in a way that supported metabolic similarities between organs of the same tissue type. The first cluster contained lipid-rich serum, head skin, abdominal skin, and thymus. The second cluster contained many organs with endocrine functions, including liver, kidney, adrenal, and pancreatic tissue. The third cluster contained gastrocnemius and quadriceps muscles, heart tissue, uterus, mammary gland, spinal cord, placenta, and ovary. In addition to this, PLS-DA showed that samples could also be distinguished based on gestational stage, and interestingly, early pregnancy (EP) was the farthest away from non-pregnant (NP) ( Figure 1E-1H ). Taken together, these results suggest that metabolic coupling exists across organ systems and that it evolves dynamically during cynomolgus monkey pregnancy.
[0104] Example 2 Evolution of metabolic coupling between maternal tissues during cynomolgus monkey pregnancy
[0105] To reveal how metabolic coupling between the 23 maternal tissues evolved over the four stages, we performed Spearman correlation analysis and used correlation heatmaps and network diagrams to visualize the results (Figure 2). The correlation heatmap showed that the correlations between the three biological replicates of each tissue were very high, further confirming the reliability of our metabolomics data ( Figures 2A-2D ). In addition, we found that the various parts within the heart and pancreas were highly similar in all four stages, as were the gastrocnemius and quadriceps muscles, or the abdominal skin and head skin, which further demonstrated the reliability of our entire pipeline from sampling, data preprocessing, and metabolomics data analysis ( Figures 2A-2D Interestingly, the correlation heat map also showed that there was a high correlation between the liver and kidney metabolomes in all four stages ( Figures 2A-2D ), indicating metabolic coupling between these two metabolically active organs.
[0106] In addition, the correlation heat map showed that the metabolic coupling between 15 tissues was dynamically evolving at different stages. For example, the metabolome of gastrocnemius and quadriceps was highly correlated with myocardial tissue in the non-pregnant state, but shifted to the adrenal gland in early and mid-pregnancy ( Figure 2A-2C By late pregnancy, both skeletal muscles were more closely connected to the spinal cord, suggesting increased neuromuscular coordination ( Figure 2D ). These results suggest that metabolic coupling between skeletal muscle and various tissues changes significantly during pregnancy.
[0107] Another interesting tissue is the placenta, which is highly associated with the uterus when it first appears in early pregnancy ( Figure 2B ), which may be related to the formation of villi between the placenta and uterus during pregnancy for the exchange of nutrients and metabolites. The uterus is more correlated with the cardiac tissue metabolome in the non-pregnant state ( Figure 2A ), but with higher coupling to placenta and pancreatic tissue in early and mid-pregnancy ( Figure 2B-2C ). However, in late pregnancy, the placenta was more metabolomically coupled to liver and heart tissue, while the uterus was more metabolomically coupled to head skin ( Figure 2D ). These results suggest that the metabolic function of uterine and placental tissues also changes significantly during pregnancy. In addition, the ovaries are highly associated with the head skin and abdominal skin in the non-pregnant state ( Figure 2A ), probably because they are both rich in epithelial tissue. However, as pregnancy progresses, their association becomes weaker and the ovary becomes more coupled to the placenta, especially in the second and third trimesters ( Figure 2C-2D ). In addition, we further constructed correlation network diagrams for the metabolomes of the 23 tissues at each stage, which more clearly showed the significant changes in metabolic coupling between skin (left), placenta (top), heart tissue (right), uterus and ovary (bottom) during pregnancy. Compared with the highly coupled non-pregnant state, the total amount of metabolic coupling between tissues decreased significantly throughout pregnancy ( Figure 2E-2H ), and reaches a highly decoupled state in late pregnancy ( Figure 2H The correlation network also shows more clearly how the emergence of the placenta coincides with a phase change in overall metabolic coupling, and how the placenta switches from being metabolically coupled to the uterus, skin, and many other tissues in early pregnancy to being metabolically coupled to ovarian and cardiac tissues in mid- and late pregnancy ( Figure 2F-2H These results suggest that the basic patterns of mutual metabolic coupling and equilibrium homeostasis between tissues are severely disrupted during pregnancy, and that the metabolic coupling patterns in multiple maternal tissues evolve in a highly coordinated manner during pregnancy.
[0108] Example 3 Changes in metabolic pathways in 23 maternal tissues during pregnancy
[0109] To further investigate the extent of metabolic reprogramming and the exact metabolic pathway changes in the 23 maternal tissues, we first analyzed which of the 11,852 annotated features changed significantly at each stage of pregnancy. Given the importance of the placenta for maintaining pregnancy, but only present in the first trimester, we used the first trimester as the baseline for all comparisons. MetaboanalystR referenced the Small Molecule Pathway Database (SMPDB) to analyze metabolic pathways enriched in significantly changed metabolites (Jewison et al., 2014; Pang et al., 2021). To quantify the extent of metabolic pathway reprogramming in the 23 maternal tissues, we counted the number of metabolic pathways that changed significantly at each stage of pregnancy (P<0.05) ( Figure 3A ). The results showed that metabolic pathways in the pancreatic neck, uterus, cardiac apex, ovary, left atrium, and thymus changed more significantly than in other tissues between non-pregnancy and early pregnancy ( Figure 3A Between early and mid-pregnancy, metabolic pathways in the uterus, pancreatic neck, pancreatic head, ovaries, spinal cord, kidneys, and head skin changed more significantly than in other tissues ( Figure 3A Between early and late pregnancy, metabolic pathways in the uterus, placenta, heart tissue, breast, adrenal gland, pancreatic tissue, liver, and abdominal skin changed more significantly than in other tissues ( Figure 3A On average, pancreatic tissue, reproductive tissue (uterus, placenta, ovaries), and cardiac tissue appear to show a higher degree of metabolic reprogramming during pregnancy.
[0110] To further reveal the large-scale changes in metabolic pathways in maternal tissues during each gestational period, we counted the number of tissues that showed significant changes in each of the 98 mapped SMPDB pathways (P<0.05). The results showed that compared with the first trimester, we found that 8 metabolic pathways were significantly changed in half or more of the maternal tissues tested at each stage of pregnancy ( Figure 3B Among these eight metabolic pathways, steroidogenesis is known to play a key role during pregnancy (Noyola-Martínez et al., 2019), while bile acid biosynthesis and arachidonic acid (an omega-6 fatty acid) metabolism are also essential pathways in maintaining pregnancy (Jadoon et al., 2014; McIlvride et al., 2017), thus confirming the validity of our findings. In addition, we observed that pyrimidine metabolism, glutamate metabolism, purine metabolism, tyrosine metabolism, and porphyrin metabolism may also be important during pregnancy.
[0111] In addition to the above eight metabolic pathways that were significantly altered in different stages of pregnancy, our results also revealed other metabolic pathways that were significantly altered in more than half of the tissues tested in each pregnancy stage ( Figure 3C and 3D ). Among the metabolic pathways that changed significantly from non-pregnancy to early pregnancy ( Figure 3C , left heat map), sphingolipid metabolism abnormalities are known to be associated with human miscarriage (Mizugishi et al., 2007), and sphingolipids are emerging as potential early pregnancy biomarkers for preeclampsia (PE) (Dobierzewska et al., 2017). In addition, we also observed significant changes in the steroid biosynthesis pathway in pancreatic tissue from early to mid-pregnancy ( Figure 3C , middle heat map), which may be related to insulin resistance and pancreatic islet function during human pregnancy (Vejrazkova et al., 2014). We also observed that many steroid pathways in maternal tissues changed significantly from early to late pregnancy, such as androgen and estrogen metabolism, estrone metabolism, steroid biosynthesis, etc. ( Figure 3C, right heat map). Interestingly, many fatty acid metabolic pathways were also significantly altered in multiple maternal tissues from early to late pregnancy ( Figure 3C , right heat map). The placenta showed the most metabolic pathway changes in late pregnancy ( Figure 3A ), further confirming our observation that the placenta is one of the most metabolically active organs during pregnancy. In summary, our pathway enrichment analysis revealed many important metabolic pathways associated with pregnancy in each maternal tissue, including some known and previously unknown ones.
[0112] Example 4 Significantly Changed Metabolites Shared by Multiple Maternal Tissues During Pregnancy
[0113] Next, we analyzed metabolites that consistently changed across pregnancy stages as potential future biomarkers and functional metabolites. We chose the first trimester as the baseline because there is no placenta in the non-pregnant state and each trimester is more comparable to each other. To quantify the results, we counted the number of differential metabolites in each tissue in the second and third trimester relative to the first trimester (fold change ≥ 1.5) and visualized the number of differential metabolites that appeared in the second and third trimesters using UpSetR Venn diagrams and circular stacked bar charts ( Figure 4 To our surprise, we found that each tissue we examined had over 3,000 differential metabolites that consistently changed in the second and third trimesters relative to the first trimester ( Figure 4 Interestingly, however, only 97 differential metabolites were shared by the 23 tissues during pregnancy ( Figure 4 ), which may be related to metabolic uncoupling caused by late pregnancy ( Figure 2H ).
[0114] Among the 97 differential metabolites, we found that palmitoylcarnitine (a well-known intermediate in fatty acid oxidation) levels were increased in the apex, right atrium, left atrium, pancreatic tail, liver, kidney, adrenal gland, and thymus during the second trimester compared with the first trimester ( et al., 1996)( Figure 5A ).
[0115] Example 5 Effects of palmitoylcarnitine on the function of human progenitor cells
[0116] The candidate metabolite palmitoylcarnitine in this application can not only act as an intermediate in fatty acid oxidation, but also regulate immune responses (Trinchese et al., 2018). Given that it continues to increase in many tissues during early and mid-pregnancy, but generally decreases during late pregnancy ( Figure 5A), we decided to further investigate whether this metabolite also mediates adaptation of maternal organs. To address this question, we induced the directed differentiation of human embryonic stem cells (hESCs) into pancreatic, liver, heart, and muscle progenitor cells (Ang et al., 2018; Chua et al., 2019; Koh et al., 2019; Martin et al., 2020), and then treated the cells with palmitoylcarnitine to continue proliferation or differentiation. For hepatic progenitor cells, palmitoylcarnitine significantly induced the terminal differentiation of hepatic progenitor cells into hepatocytes expressing ALB, and the expression of ALB increased in a dose-dependent manner, but did not affect specific factors of hepatic progenitor cells, suggesting that it may have the effect of accelerating regeneration after maternal liver injury ( Figure 5B In muscle progenitor cells, palmitoylcarnitine decreased levels of the myoblast transcription factor PAX3 and increased the differentiated myocyte transcription factor MYOG in a dose-dependent manner, suggesting that it may regulate maternal muscle growth and differentiation in response to stress and injury ( Figure 5C Palmitoylcarnitine can also induce the specialization and differentiation of cardiomyocytes, as observed from the dose-dependent increase in the expression of ISL1 and TNNT2 ( Figure 5D ), indicating that it can promote maternal heart growth during pregnancy. In addition, palmitoylcarnitine can also induce the specialization and terminal differentiation of pancreatic β-islet cells, which can be observed from the increase in PAX4 and RFX6 expression ( Figure 5E ), suggesting that it can promote regeneration of maternal pancreatic β-islet cells during normal pregnancy. Taken together, these results suggest that sustained increases in palmitoylcarnitine in many tissues during early and mid-pregnancy may play a functional role in regulating maternal organ growth and regeneration, whereas the effects of palmitoylcarnitine gradually diminish in late pregnancy.
[0117] Although the embodiments of the present invention are described above in conjunction with the accompanying drawings, the present invention is not limited to the above specific embodiments and application fields, and the above specific embodiments are only illustrative and instructive, rather than restrictive. A person of ordinary skill in the art can also make many forms under the guidance of this specification and without departing from the scope of protection of the claims of the present invention, all of which belong to the protection of the present invention.
[0118] References
[0119] Aasa,K.L.,Zavan,B.,Luna,R.L.,Wong,P.G.,Ventura,N.M.,Tse,M.Y.,Carmeliet,P.,Adams,M.A.,Pang,S.C.,and Croy,B.A.(2015).Placental growth factorinfluences maternal cardiovascular adaptation to pregnancy in mice.Biology ofreproduction 92,44.
[0120] 10.1095 / biolreprod.114.124677.
[0121] Alkema,L.,Chou,D.,Hogan,D.,Zhang,S.,Moller,A.B.,Gemmill,A.,Fat,D.M.,Boerma,T.,Temmerman,M.,Mathers,C.,et al.(2016).Global,regional,and nationallevels and trends in maternal mortality between 1990 and 2015,with scenario-based projections to 2030:a systematic analysis by the UN Maternal MortalityEstimation Inter-Agency Group.Lancet(London,England)387,462-474.
[0122] 10.1016 / S0140-6736(15)00838-7.
[0123] Alsat,E.,Guibourdenche,J.,Luton,D.,Frankenne,F.,and Evain-Brion,D.(1997).Human placental growth hormone.American journal of obstetrics andgynecology 177,1526-1534.
[0124] 10.1016 / s0002-9378(97)70103-0.
[0125] Ang,L.T.,Tan,A.K.Y.,Autio,M.I.,Goh,S.H.,Choo,S.H.,Lee,K.L.,Tan,J.,Pan,B.,Lee,J.J.H.,Lum,J.J.,et al.(2018).A Roadmap for Human LiverDifferentiation from Pluripotent Stem Cells.Cell reports 22,2190-2205.
[0126] 10.1016 / j.celrep.2018.01.087.
[0127] Bonkovsky,H.L.,Guo,J.T.,Hou,W.,Li,T.,Narang,T.,and Thapar,M.(2013).Porphyrin and heme metabolism and the porphyrias.Comprehensive Physiology 3,365-401.
[0128] 10.1002 / cphy.c120006.
[0129] Bricker,L.,and Neilson,J.P.(2000).Routine doppler ultrasound inpregnancy.The Cochrane database of systematic reviews,Cd001450.
[0130] 10.1002 / 14651858.CD001450.
[0131] Brown,M.A.,Magee,L.A.,Kenny,L.C.,Karumanchi,S.A.,McCarthy,F.P.,Saito,S.,Hall,D.R.,Warren,C.E.,Adoyi,G.,and Ishaku,S.(2018).The hypertensivedisorders of pregnancy:ISSHP classification,diagnosis&managementrecommendations for international practice.Pregnancy hypertension 13,291-310.
[0132] 10.1016 / j.preghy.2018.05.004.
[0133] Burke,S.J.,Batdorf,H.M.,Huang,T.Y.,Jackson,J.W.,Jones,K.A.,Martin,T.M.,Rohli,K.E.,Karlstad,M.D.,Sparer,T.E.,Burk,D.H.,et al.(2019).One week ofcontinuous corticosterone exposure impairs hepatic metabolic flexibility,promotes isletβ-cell proliferation,and reduces physical activity in maleC57BL / 6J mice.The Journal of steroid biochemistry and molecular biology 195,105468.
[0134] 10.1016 / j.jsbmb.2019.105468.
[0135] Buse,E.,and Markert,U.R.(2019).The immunology of the macaqueplacenta:A detailed analysis and critical comparison with the humanplacenta.Critical reviews in clinical laboratory sciences 56,118-145.10.1080 / 10408363.2018.1538200.
[0136] Cakmak,M.,Yilmaz,H., E.,Darcin,T.,Inan,O.,Aktas,A.,Celik,H.T.,Ozdemir,O.,Atalay,C.R.,and Akcay,A.(2016).Serum levels of endocan correlatewith the presence and severity of pre-eclampsia.Clinical and experimentalhypertension(New York,NY:1993)38,137-142.
[0137] 10.3109 / 10641963.2015.1060993.
[0138] Chang,J.,and Streitman,D.(2012).Physiologic adaptations topregnancy.Neurologic clinics 30,781-789.
[0139] 10.1016 / j.ncl.2012.05.001.
[0140] Chua,M.J.,Yildirim,E.D.,Tan,J.E.,Chua,Y.B.,Low,S.C.,Ding,S.L.S.,Li,C.W.,Jiang,Z.,Teh,B.T.,Yu,K.,et al.(2019).Assessment of different strategiesfor scalable production and proliferation of human myoblasts.Cellproliferation 52,e12602.
[0141] 10.1111 / cpr.12602.
[0142] Conway,J.R.,Lex,A.,and Gehlenborg,N.(2017).UpSetR:an R package forthe visualization of intersecting sets and their properties.Bioinformatics(Oxford,England)33,2938-2940.
[0143] 10.1093 / bioinformatics / btx364.
[0144] De Martino,D.,McAndersson,A.,Bergmiller,T.,Guet,C.C.,and G.(2018).Statistical mechanics for metabolic networks during steady stategrowth.Nature communications 9,2988.
[0145] 10.1038 / s41467-018-05417-9.
[0146] Dixit,V.D.,Sridaran,R.,Edmonsond,M.A.,Taub,D.,and Thompson,W.E.(2003).Gonadotropin-releasing hormone attenuates pregnancy-associated thymicinvolution and modulates the expression of antiproliferative gene productprohibitin.Endocrinology 144,1496-1505.
[0147] 10.1210 / en.2002-220955.
[0148] Dobierzewska,A.,Soman,S.,Illanes,S.E.,and Morris,A.J.(2017).Plasmacross-gestational sphingolipidomic analyses reveal potential first trimesterbiomarkers of preeclampsia.PloS one 12,e0175118.
[0149] 10.1371 / journal.pone.0175118.
[0150] H.G.,Heller,A.,Versmold,H.T.,Sippell,W.G.,Herrmann,M.,Bidlingmaier,F.,and Knorr,D.(1989).Longitudinal study of progestins,mineralocorticoids,and glucocorticoids throughout human pregnancy.The Journalof clinical endocrinology and metabolism 68,863-868.
[0151] 10.1210 / jcem-68-5-863.
[0152] Ellery,S.J.,LaRosa,D.A.,Kett,M.M.,Della Gatta,P.A.,Snow,R.J.,Walker,D.W.,and Dickinson,H.(2015).Maternal creatine homeostasis is altered duringgestation in the spiny mouse:is this a metabolic adaptation to pregnancy?BMCpregnancy and childbirth 15,92.
[0153] 10.1186 / s12884-015-0524-1.
[0154] Epskamp,S.,Cramer,A.O.J.,Waldorp,L.J.,Schmittmann,V.D.,and Borsboom,D.(2012).qgraph:Network Visualizations of Relationships in PsychometricData.Journal of Statistical Software 48,1-18.10.18637 / jss.v048.i04
[0155] Fowden,A.L.,and Forhead,A.J.(2015).Glucocorticoids as regulatorysignals during intrauterine development.Experimental physiology 100,1477-1487.
[0156] 10.1113 / EP085212.Epub 2015 Jul 14.
[0157] Frayn,K.N.,Arner,P.,and Yki- H.(2006).Fatty acid metabolism inadipose tissue,muscle and liver in health and disease.Essays in biochemistry42,89-103.
[0158] 10.1042 / bse0420089.
[0159] Friess,E.,Schiffelholz,T.,Steckler,T.,and Steiger,A.(2000).Dehydroepiandrosterone--a neurosteroid.European journal of clinicalinvestigation 30 Suppl 3,46-50.
[0160] 10.1046 / j.1365-2362.2000.0300s3046.x.
[0161] Garrido,A.(2011).Symmetry in Complex Networks.Symmetry 3,1-15.
[0162] 10.3390 / sym3010001.
[0163] Ghayee,H.K.,and Auchus,R.J.(2007).Basic concepts and recentdevelopments in human steroid hormone biosynthesis.Reviews in endocrine&metabolic disorders 8,289-300.
[0164] 10.1007 / s11154-007-9052-2.
[0165] F.M.,Requero,M.A.,and Alonso,A.(1996).Palmitoylcarnitine,asurface-active metabolite.FEBS letters 390,1-5.
[0166] 10.1016 / 0014-5793(96)00603-5.
[0167] Grossmann,H.,Weinbauer,G.F.,Baker,A.,Fuchs,A.,and Luetjens,C.M.(2020).Enhanced normograms and pregnancy outcome analysis in nonhuman primatedevelopmental toxicity studies.Reproductive toxicology(Elmsford,NY)95,29-36.
[0168] 10.1016 / j.reprotox.2020.04.074.
[0169] Heidegger,H.,and Jeschke,U.(2018).Human Chorionic Gonadotropin(hCG)-An Endocrine,Regulator of Gestation and Cancer.International journal ofmolecular sciences 19.
[0170] 10.3390 / ijms19051502.
[0171] Hemberger,M.,Hanna,C.W.,and Dean,W.(2020).Mechanisms of earlyplacental development in mouse and humans.Nature reviews Genetics 21,27-43.
[0172] 10.1038 / s41576-019-0169-4.
[0173] Henley,D.,Brown,S.,Pennell,C.,Lye,S.,and Torpy,D.J.(2016).Evidencefor central hypercortisolism and elevated blood pressure in adolescentoffspring of mothers with pre-eclampsia.Clinical endocrinology 85,583-589.
[0174] 10.1111 / cen.13092.
[0175] Ho,J.T.,Lewis,J.G.,O'Loughlin,P.,Bagley,C.J.,Romero,R.,Dekker,G.A.,and Torpy,D.J.(2007).Reduced maternal corticosteroid-binding globulin andcortisol levels in pre-eclampsia and gamete recipient pregnancies.Clinicalendocrinology 66,869-877.
[0176] 10.1111 / j.1365-2265.2007.02826.x.
[0177] Hofmeyr,J.H.,and Rohwer,J.M.(2011).Supply-demand analysis a frameworkfor exploring the regulatory design of metabolism.Methods in enzymology 500,533-554.
[0178] 10.1016 / B978-0-12-385118-5.00025-6.
[0179] Hug,L.,Alexander,M.,You,D.,and Alkema,L.(2019).National,regional,andglobal levels and trends in neonatal mortality between 1990 and 2017,withscenario-based projections to 2030:a systematic analysis.The Lancet Globalhealth 7,e710-e720.
[0180] 10.1016 / S2214-109X(19)30163-9.
[0181] Innes,J.K.,and Calder,P.C.(2018).Omega-6 fatty acids andinflammation.Prostaglandins,leukotrienes,and essential fatty acids 132,41-48.
[0182] 10.1016 / j.plefa.2018.03.004.
[0183] T., O.,Jokkala,J., A.,Heinonen,S.,Auriola,S.,Lehtonen,M.,Hanhineva,K.,and Laivuori,H.(2021).A non-targeted LC-MS metabolicprofiling of pregnancy:longitudinal evidence from healthy and pre-eclampticpregnancies.Metabolomics:Official journal of the Metabolomic Society 17,20.
[0184] 10.1007 / s11306-020-01752-5.
[0185] Jadoon,A.,Cunningham,P.,and McDermott,L.C.(2014).Arachidonic acidmetabolism in the human placenta:identification of a putativelipoxygenase.Placenta 35,422-424.
[0186] 10.1016 / j.placenta.2014.03.024.
[0187] Jaffe,E.K.(2004).The porphobilinogen synthase catalyzed reactionmechanism.Bioorganic chemistry 32,316-325.
[0188] 10.1016 / j.bioorg.2004.05.010.
[0189] Jayasuriya,N.A.,Hughes,A.E.,Sovio,U.,Cook,E.,Charnock-Jones,D.S.,andSmith,G.C.S.(2019).A Lower Maternal Cortisol-to-Cortisone Ratio PrecedesClinical Diagnosis of Preterm and Term Preeclampsia by Many Weeks.The Journalof clinical endocrinology and metabolism 104,2355-2366.10.1210 / jc.2018-02312.
[0190] Jewison,T.,Su,Y.,Disfany,F.M.,Liang,Y.,Knox,C.,Maciejewski,A.,Poelzer,J.,Huynh,J.,Zhou,Y.,Arndt,D.,et al.(2014).SMPDB 2.0:big improvementsto the Small Molecule Pathway Database.Nucleic acids research 42,D478-484.
[0191] 10.1093 / nar / gkt1067.
[0192] Kodaman,P.H.,and Taylor,H.S.(2004).Hormonal regulation ofimplantation.Obstetrics and gynecology clinics of North America 31,745-766,ix.
[0193] 10.1016 / j.ogc.2004.08.008.
[0194] Koh,P.W.,Sinha,R.,Barkal,A.A.,Morganti,R.M.,Chen,A.,Weissman,I.L.,Ang,L.T.,Kundaje,A.,and Loh,K.M.(2016).An atlas of transcriptional,chromatinaccessibility,and surface marker changes in human mesodermdevelopment.Scientific data 3,160109.
[0195] 10.1038 / sdata.2016.109.
[0196] Kosicka,K., ,A., M., ,G.H.,Resztak,M.,Majchrzak-Celińska,A.,Chuchracki,M.,and ,F.K.(2015).GlucocorticoidMetabolism in Hypertensive Disorders of Pregnancy:Analysis of Plasma andUrinary Cortisol and Cortisone.PloS one 10,e0144343.
[0197] 10.1371 / journal.pone.0144343.
[0198] Larsson,A.,Palm,M.,Hansson,L.O.,and Axelsson,O.(2008).Referencevalues for clinical chemistry tests during normal pregnancy.BJOG:aninternational journal of obstetrics and gynaecology 115,874-881.
[0199] 10.1111 / j.1471-0528.2008.01709.x.
[0200] Lewis,R.M.,Wadsack,C.,and Desoye,G.(2018).Placental fatty acidtransfer.Current opinion in clinical nutrition and metabolic care 21,78-82.
[0201] 10.1097 / MCO.0000000000000443.
[0202] Liang,L.,Rasmussen,M.H.,Piening,B.,Shen,X.,Chen,S., H.,Snyder,J.K.,Tibshirani,R.,Skotte,L.,Lee,N.C.,et al.(2020).Metabolic Dynamics andPrediction of Gestational Age and Time to Delivery in Pregnant Women.Cell181,1680-1692.e1615.
[0203] 10.1016 / j.cell.2020.05.002.
[0204] Lindsay,K.L.,Hellmuth,C.,Uhl,O.,Buss,C.,Wadhwa,P.D.,Koletzko,B.,andEntringer,S.(2015).Longitudinal Metabolomic Profiling of Amino Acids andLipids across Healthy Pregnancy.PloS one 10,e0145794.
[0205] 10.1371 / journal.pone.0145794.
[0206] Liu,J.,Yuan,E.,and Lee,L.(2012).Gestational age-specific referenceintervals for routine haemostatic assays during normal pregnancy.Clinicachimica acta;international journal of clinical chemistry 413,258-261.
[0207] 10.1016 / j.cca.2011.09.046.
[0208] Martin,R.M.,Fowler,J.L.,Cromer,M.K.,Lesch,B.J.,Ponce,E.,Uchida,N.,Nishimura,T.,Porteus,M.H.,and Loh,K.M.(2020).Improving the safety of humanpluripotent stem cell therapies using genome-edited orthogonalsafeguards.Nature communications 11,2713.
[0209] 10.1038 / s41467-020-16455-7.
[0210] Mayhew,T.M.(2006).Allometric studies on growth and development of thehuman placenta:growth of tissue compartments and diffusive conductances inrelation to placental volume and fetal mass.Journal of anatomy 208,785-794.
[0211] 10.1111 / j.1469-7580.2006.00566.x.
[0212] McIlvride,S.,Dixon,P.H.,and Williamson,C.(2017).Bile acids andgestation.Molecular aspects of medicine 56,90-100.
[0213] 10.1016 / j.mam.2017.05.003.
[0214] Melit Devassy,B.,George,S.,and Nussbaum,P.(2020).UnsupervisedClustering of Hyperspectral Paper Data Using t-SNE.Journal of imaging 6.
[0215] 10.3390 / jimaging6050029.
[0216] Mennitti,L.V.,Oliveira,J.L.,Morais,C.A.,Estadella,D.,Oyama,L.M.,Ollerdo Nascimento,C.M.,and Pisani,L.P.(2015).Type of fatty acids in maternaldiets during pregnancy and / or lactation and metabolic consequences of theoffspring.The Journal of nutritional biochemistry 26,99-111.
[0217] 10.1016 / j.jnutbio.2014.10.001.
[0218] Mihm,M.,Gangooly,S.,and Muttukrishna,S.(2011).The normal menstrualcycle in women.Animal reproduction science 124,229-236.
[0219] 10.1016 / j.anireprosci.2010.08.030.
[0220] Mizugishi,K.,Li,C.,Olivera,A.,Bielawski,J.,Bielawska,A.,Deng,C.X.,andProia,R.L.(2007).Maternal disturbance in activated sphingolipid metabolismcauses pregnancy loss in mice.The Journal of clinical investigation 117,2993-3006.
[0221] 10.1172 / JCI30674.
[0222] Mora,F.,Segovia,G.,Del Arco,A.,de Blas,M.,and Garrido,P.(2012).Stress,neurotransmitters,corticosterone and body-brain integration.Brainresearch 1476,71-85.
[0223] 10.1016 / j.brainres.2011.12.049.
[0224] Most,J.,Marlatt,K.L.,Altazan,A.D.,and Redman,L.M.(2018).Advances inassessing body composition during pregnancy.European journal of clinicalnutrition 72,645-656.
[0225] 10.1038 / s41430-018-0152-8.
[0226] Ng,SW,Norwitz,GA,Pavlicev,M.,Tilburgs,T.,Simón,C.,and Norwitz,ER(2020).Endometrial Decidualization:The Primary Driver of PregnancyHealth.International journal of molecular sciences 21.10.3390 / ijms 149211.
[0227] Noyola-Martínez,N.,Halhali,A.,and Barrera,D.(2019).Steroid hormonesand pregnancy.Gynecological endocrinology:the official journal of theInternational Society of Gynecological Endocrinology 35,376-384.
[0228] 10.1080 / 09513590.2018.1564742.
[0229] Orczyk-Pawilowicz,M.,Jawien,E.,Deja,S.,Hirnle,L.,Zabek,A.,andMlynarz,P.(2016).Metabolomics of Human Amniotic Fluid and Maternal Plasmaduring Normal Pregnancy.PloS one 11,e0152740.
[0230] 10.1371 / journal.pone.0152740.
[0231] Pang,Z.,Chong,J.,Zhou,G.,de Lima Morais,D.A.,Chang,L.,Barrette,M.,Gauthier,C.,Jacques,P.,Li,S.,and Xia,J.(2021).MetaboAnalyst 5.0:narrowing thegap between raw spectra and functional insights.Nucleic acids research 49,W388-w396.
[0232] 10.1093 / nar / gkab382.
[0233] Papacleovoulou,G.,Nikolova,V.,Oduwole,O.,Chambers,J.,Vazquez-Lopez,M.,Jansen,E.,Nicolaides,K.,Parker,M.,and Williamson,C.(2017).Gestationaldisruptions in metabolic rhythmicity of the liver,muscle,and placenta affectfetal size.FASEB journal:official publication of the Federation of AmericanSocieties for Experimental Biology 31,1698-1708.
[0234] 10.1096 / fj.201601032R.
[0235] Paquette,A.,Baloni,P.,Holloman,A.B.,Nigam,S.,Bammler,T.,Mao,Q.,andPrice,N.D.(2018).Temporal transcriptomic analysis of metabolic genes inmaternal organs and placenta during murine pregnancy.Biology of reproduction99,1255-1265.
[0236] 10.1093 / biolre / ioy148.
[0237] Patel,O.V.,Casey,T.,Dover,H.,and Plaut,K.(2011).Homeorheticadaptation to lactation:comparative transcriptome analysis of mammary,liver,and adipose tissue during the transition from pregnancy to lactation inrats.Functional&integrative genomics 11,193-202.
[0238] 10.1007 / s10142-010-0193-0.
[0239] Perazzolo,S.,Hirschmugl,B.,Wadsack,C.,Desoye,G.,Lewis,R.M.,andSengers,B.G.(2015).Computational modelling of fatty acid transport in thehuman placenta.Annual International Conference of the IEEE Engineering inMedicine and Biology Society IEEE Engineering in Medicine and BiologySocietyAnnual International Conference 2015,8054-8057.
[0240] 10.1109 / EMBC.2015.7320262.
[0241] Peters,V.,Klessens,C.Q.,Baelde,H.J.,Singler,B.,Veraar,K.A.,Zutinic,A.,Drozak,J.,Zschocke,J.,Schmitt,C.P.,and de Heer,E.(2015).Intrinsiccarnosine metabolism in the human kidney.Amino acids 47,2541-2550.
[0242] 10.1007 / s00726-015-2045-7.
[0243] Plaza-Parrochia,F.,Romero,C.,Valladares,L.,and Vega,M.(2017).Endometrium and steroids,a pathologic overview.Steroids 126,85-91.
[0244] 10.1016 / j.steroids.2017.08.007.
[0245] Ramlakhan,K.P.,Johnson,M.R.,and Roos-Hesselink,J.W.(2020).Pregnancyand cardiovascular disease.Nature reviews Cardiology 17,718-731.
[0246] 10.1038 / s41569-020-0390-z.
[0247] Revollo,J.R.,and Cidlowski,J.A.(2009).Mechanisms generating diversityin glucocorticoid receptor signaling.Annals of the New YorkAcademy ofSciences 1179,167-178.
[0248] 10.1111 / j.1749-6632.2009.04986.x.
[0249] Reyes,J.L.(1993).Arachidonic acid metabolites and haemodynamics ofthe neonate.Pediatric nephrology(Berlin,Germany)7,841-844.
[0250] 10.1007 / BF01213371.
[0251] Rieck,S.,and Kaestner,K.H.(2010).Expansion of beta-cell mass inresponse to pregnancy.Trends in endocrinology and metabolism:TEM 21,151-158.
[0252] 10.1016 / j.tem.2009.11.001.
[0253] Ruebel,M.L.,Gilley,S.P.,Sims,C.R.,Zhong,Y.,Turner,D.,Chintapalli,S.V.,Piccolo,B.D.,Andres,A.,and Shankar,K.(2021).Associations betweenMaternal Diet,Body Composition and Gut Microbial Ecology inPregnancy.Nutrients 13.
[0254] 10.3390 / nu13093295.
[0255] Saoi,M.,Kennedy,K.M.,Gohir,W.,Sloboda,D.M.,and Britz-McKibbin,P.(2020).Placental Metabolomics for Assessment of Sex-specific Differences inFetal Development During Normal Gestation.Scientific reports 10,9399.
[0256] 10.1038 / s41598-020-66222-3.
[0257] Seidel,T.,Fiegle,D.J.,Baur,T.J.,Ritzer,A.,Nay,S.,Heim,C.,Weyand,M.,Milting,H.,Oakley,R.H.,Cidlowski,J.A.,et al.(2019).Glucocorticoids preservethe t-tubular system in ventricular cardiomyocytes by upregulation ofautophagic flux.Basic research in cardiology 114,47.
[0258] 10.1007 / s00395-019-0758-6.
[0259] Sharma,D.,Singh,A.,Trivedi,S.S.,and Bhattacharjee,J.(2011).Role ofendothelin and inflammatory cytokines in pre-eclampsia-A pilot North Indianstudy.American journal of reproductive immunology(New York,NY:1989)65,428-432.
[0260] 10.1111 / j.1600-0897.2010.00903.x.
[0261] Shyh-Chang,N.,Locasale,J.W.,Lyssiotis,C.A.,Zheng,Y.,Teo,R.Y.,Ratanasirintrawoot,S.,Zhang,J.,Onder,T.,Unternaehrer,J.J.,Zhu,H.,et al.(2013).Influence of threonine metabolism on S-adenosylmethionine and histonemethylation.Science(New York,NY)339,222-226.
[0262] 10.1126 / science.1226603.
[0263] Sieck,G.C.(2019).Physiology in Perspective:Of Mice and Men.Physiology(Bethesda,Md)34,3-4.10.1152 / physiol.00049.2018.
[0264] Sley,E.G.,Rosen,E.M.,van't Erve,T.J.,Sathyanarayana,S.,Barrett,E.S.,Nguyen,R.H.N.,Bush,N.R.,Milne,G.L.,Swan,S.H.,and Ferguson,K.K.(2020).Omega-3fatty acid supplement use and oxidative stress levels in pregnancy.PloS one15,e0240244.
[0265] 10.1371 / journal.pone.0240244.
[0266] Spencer,R.L.,and Deak,T.(2017).A users guide to HPA axisresearch.Physiology&behavior 178,43-65.
[0267] 10.1016 / j.physbeh.2016.11.014.
[0268] Svennersten-Sjaunja,K.,and Olsson,K.(2005).Endocrinology of milkproduction.Domestic animal endocrinology 29,241-258.
[0269] 10.1016 / j.domaniend.2005.03.006.
[0270] Szarka,A.,Rigó,J.,Jr.,Lázár,L.,Beko,G.,and Molvarec,A.(2010).Circulating cytokines,chemokines and adhesion molecules in normal pregnancyand preeclampsia determined by multiplex suspension array.BMC immunology 11,59.
[0271] 10.1186 / 1471-2172-11-59.
[0272] Szlapinski,S.K.,and Hill,D.J.(2021).Metabolic Adaptations toPregnancy in Healthy and Gestational Diabetic Pregnancies:The Pancreas-Placenta Axis.Current vascular pharmacology 19,141-153.
[0273] 10.2174 / 1570161118666200320111209.
[0274] Tosun,M.,Celik,H.,Avci,B.,Yavuz,E.,Alper,T.,and E.(2010).Maternal and umbilical serum levels of interleukin-6,interleukin-8,and tumornecrosis factor-alpha in normal pregnancies and in pregnancies complicated bypreeclampsia.The journal of maternal-fetal&neonatal medicine:the officialjournal of the European Association of Perinatal Medicine,the Federation ofAsia and Oceania Perinatal Societies,the International Society of PerinatalObstet 23,880-886.
[0275] 10.3109 / 14767051003774942.
[0276] Trinchese,G.,Paparo,L.,Aitoro,R.,Fierro,C.,Varchetta,M.,Nocerino,R.,Mollica,M.P.,and Berni Canani,R.(2018).Hepatic Mitochondrial Dysfunction andImmune Response in a Murine Model of PeanutAllergy.Nutrients 10.
[0277] 10.3390 / nu10060744.
[0278] Unrean,P.,and Srienc,F.(2011).Metabolic networks evolve towardsstates of maximum entropy production.Metabolic engineering 13,666-673.
[0279] 10.1016 / j.ymben.2011.08.003.
[0280] Vejrazkova,D.,Vcelak,J.,Vankova,M.,Lukasova,P.,Bradnova,O.,Halkova,T.,Kancheva,R.,and Bendlova,B.(2014).Steroids and insulin resistance inpregnancy.The Journal of steroid biochemistry and molecular biology 139,122-129.
[0281] 10.1016 / j.jsbmb.2012.11.007.
[0282] Verbeek,A.L.,and Verbeek,A.J.(2014).Timely assessment ofcardiovascular risk after preeclampsia.
[0283] Women's health(London,England)10,557-559.
[0284] 10.2217 / whe.14.53.
[0285] von Versen-Hoeynck,F.M.,and Powers,R.W.(2007).Maternal-fetalmetabolism in normal pregnancy and preeclampsia.Frontiers in bioscience:ajournal and virtual library 12,2457-2470.
[0286] 10.2741 / 2247.
[0287] Wagner,J.E.,Kavanagh,K.,Ward,G.M.,Auerbach,B.J.,Harwood,H.J.,Jr.,andKaplan,J.R.(2006).Old world nonhuman primate models of type 2 diabetesmellitus.ILAR journal 47,259-271.
[0288] 10.1093 / ilar.47.3.259.
[0289] Wang,Q.,Würtz,P.,Auro,K., V.P.,Kangas,A.J.,Soininen,P.,Tiainen,M.,Tynkkynen,T.,Jokelainen,J.,Santalahti,K.,et al.(2016).Metabolic profilingof pregnancy:cross-sectional and longitudinal evidence.BMC medicine 14,205.
[0290] 10.1186 / s12916-016-0733-0.
[0291] Wang,R.,Hartmann,M.F.,Tiosano,D.,and Wudy,S.A.(2019).Characterizingthe steroidal milieu in amniotic fluid of mid-gestation:A GC-MS study.TheJournal of steroid biochemistry and molecular biology 193,105412.
[0292] 10.1016 / j.jsbmb.2019.105412.
[0293] Wang,Y.,Viscarra,J.,Kim,S.J.,and Sul,H.S.(2015).Transcriptionalregulation of hepatic lipogenesis.Nature reviews Molecular cell biology 16,678-689.
[0294] 10.1038 / nrm4074.
[0295] Wang,Y.,Wu,H.,Jiang,X.,Jia,L.,Wang,M.,Rong,Y.,Chen,S.,Wang,Y.,Xiao,Z.,Liang,X.,et al.(2022).LMNA Determines Nuclear Morphology DuringSyncytialization of Human Trophoblast Stem Cells.Frontiers in cell anddevelopmental biology 10,836390.
[0296] 10.3389 / fcell.2022.836390.eCollection 2022.
[0297] Wei,J.,Chen,S.,Guo,W.,Feng,B.,Yang,S.,Huang,C.,and Chu,J.(2018).Leukotriene D4 induces cellular senescence in osteoblasts.Internationalimmunopharmacology 58,154-159.
[0298] 10.1016 / j.intimp.2017.12.027.
[0299] Weinbauer,G.F.,Niehoff,M.,Niehaus,M.,Srivastav,S.,Fuchs,A.,Van Esch,E.,and Cline,J.M.(2008).Physiology and Endocrinology of the Ovarian Cycle inMacaques.Toxicologic pathology 36,7s-23s.
[0300] 10.1177 / 0192623308327412.
[0301] Widen,E.M.,and Gallagher,D.(2014).Body composition changes inpregnancy:measurement,predictors and outcomes.European journal of clinicalnutrition 68,643-652.
[0302] 10.1038 / ejcn.2014.40.
[0303] Wilken,J.A.,Matsumoto,K.,Laughlin,L.S.,Lasley,B.L.,and Bedows,E.(2002).Comparison of chorionic gonadotropin expression in human and macaque(Macaca fascicularis)trophoblasts.American journal of primatology 56,89-97.
[0304] 10.1002 / ajp.1066.
[0305] Xia,J.,and Wishart,D.S.(2010).MSEA:a web-based tool to identifybiologically meaningful patterns in quantitative metabolomic data.Nucleicacids research 38,W71-77.
[0306] 10.1093 / nar / gkq329.
[0307] Yan,G.,Zhang,G.,Fang,X.,Zhang,Y.,Li,C.,Ling,F.,Cooper,D.N.,Li,Q.,Li,Y.,van Gool,A.J.,et al.(2011).Genome sequencing and comparison of twononhuman primate animal models,the cynomolgus and Chinese rhesusmacaques.Nature biotechnology 29,1019-1023.
[0308] 10.1038 / nbt.1992.
[0309] Yang,Q.,Wang,W.,Liu,C.,Wang,Y.,and Sun,K.(2016).Compartmentalizedlocalization of 11β-HSD 1 and 2 at the feto-maternal interface in the firsttrimester of human pregnancy.Placenta 46,63-71.
[0310] 10.1016 / j.placenta.2016.08.079.
[0311] Ye,J.,and Medzhitov,R.(2019).Control strategies in systemicmetabolism.Nature metabolism 1,947-957.
[0312] 10.1038 / s42255-019-0118-8.
[0313] Yoshida,T.,Hanari,K.,Fujimoto,K.,and Sankai,T.(2010).Femalereproduction characteristics in a large-scale breeding colony of cynomolgusmonkeys(Macaca fascicularis).Experimental animals 59,251-254.
[0314] 10.1538 / expanim.59.251.
[0315] Zeng,Z.,Liu,F.,and Li,S.(2017).Metabolic Adaptations in Pregnancy:AReview.Annals of nutrition&metabolism 70,59-65.
[0316] 10.1159 / 000459633.
[0317] Zhang,H.,Bastian,J.R.,Zhao,W.,Chen,H.,Shaik,I.H.,Chaphekar,N.,Caritis,S.N.,and Venkataramanan,R.(2020).Pregnancy Alters CYP-and UGT-Mediated Metabolism of Buprenorphine.Therapeutic drug monitoring 42,264-270.
[0318] 10.1097 / FTD.0000000000000724.
[0319] Zhao,X.,Chen,S.,Zhao,C.,and Xia,F.(2021).Maternal Immune System andState of Inflammation Dictate the Fate and Severity of Disease inPreeclampsia.Journal of immunology research 2021,9947884.
[0320] 10.1155 / 2021 / 9947884.eCollection 2021.
Claims
1. The use of palmitoylcarnitine in the preparation of drugs for treating heart disease, gestational diabetes and liver disease during pregnancy in mammals.
2. The use according to claim 1, wherein The mammal is a human.
3. The use according to claim 1, wherein: The mammals are animals raised by humans.
4. The use according to claim 3, wherein: The human-reared animal is selected from any one of the following groups: pigs, cows, horses, dogs, cats, goats, rabbits, cynomolgus macaques, mice, and rats.
5. The use according to claim 1, wherein The palmitoylcarnitine realizes tissue regeneration by promoting the growth and differentiation of progenitor cells when tissue is damaged during pregnancy.
